A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys)180 microg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PADD-ON
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Apr 2016 Results of interim analysis at week 24 (n=137) as well as safety data (n=160) presented at The International Liver Congress™ 2016.
- 01 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.